Navigation Links
Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
Date:8/19/2007

Dr. David S. Smith to Head Regulatory and Quality Affairs

DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Audrey F. Jakubowski, Ph.D., Chief Regulatory and Quality Officer will retire effective today. Dr. Jakubowski's primary responsibilities have been transitioned to David S. Smith, Ph.D., who earlier this year joined SuperGen as Vice President, Regulatory and Quality Affairs.

"Dr. Jakubowski has been extremely instrumental in guiding and growing SuperGen's regulatory and quality efforts over the years," said Dr. James Manuso, President and CEO. "A valued colleague, Audrey created and nurtured a highly effective organization and approach to regulatory affairs and quality management that the Company will continue under Dr. David Smith's leadership."

Dr. Smith, 52, joined SuperGen in March 2007. Prior to joining SuperGen, Dr. Smith was Senior Director, Regulatory Strategy at Wyeth Consumer Healthcare. His responsibilities included obtaining new product registrations on a global level, US marketed product support, and providing scientific and regulatory guidance to business development initiatives. From 1996 to 2000, Dr. Smith served as Regulatory Affairs Program Director at Roche Pharma. Dr. Smith began his regulatory career in 1987 at Schering-Plough, where he focused on the development and registration of oncology and biotechnology products. During his tenure at Schering-Plough, he concentrated on European Union activities and major markets outside of the U.S. Dr. Smith's training includes a post-doctoral fellowship and research in biochemical genetics at the Roche Institute of Molecular Biology. He received a Ph.D. in pharmacology from Wayne State University School of Medicine, and a B.S. in Biophysics, also from Wayne State University.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. State technology chief endorses IT audit recommendations
2. Fusion 2007: CA chief says IT complexity raises risk
3. Web-Based Learning Developed under new Chief Education Officer
4. BD IMag Human Regulatory T Lymphocyte Separation Set for Isolation of Treg Cells
5. Emergence of Internet video is changing the regulatory landscape
6. To attract investment, convince manufacturers that regulatory reform is real
7. Support Regulatory Change to Boost Wisconsins Biotech Sector
8. A Simple and Rapid Technique to Purify High-Quality Midiprep DNA
9. Generate High-Quality, Directional Plasmid cDNA Libraries
10. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
11. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):